Do All High- and Intermediate-Risk Patients With Metastatic Castration-Resistant Prostate Cancer Really Benefit From Abiraterone?

J Clin Oncol. 2016 Feb 1;34(4):387. doi: 10.1200/JCO.2015.62.8537. Epub 2015 Nov 23.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Androstenes / therapeutic use*
  • Biomarkers, Tumor / analysis*
  • Humans
  • Male
  • Neoplastic Cells, Circulating / pathology*
  • Prostatic Neoplasms, Castration-Resistant / pathology*

Substances

  • Androstenes
  • Biomarkers, Tumor